Suchergebnisse - "Voog, Eric"

PubPharm (86)

1

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma : Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Motzer, R. | Porta, C. | Eto, M. | +134

2

A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer : Patient Preference and Cognitive Function in ODENZA

enthalten in: European urology | 2024

von Colomba, E. | Jonas, S. | Eymard, J. | +21

3

Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER) : survival endpoints at 5 years in an open-label, randomised, phase 3 study

enthalten in: The Lancet. Oncology | 2024

von Pfister, C. | Gravis, G. | Flechon, A. | +53

4

Publisher Correction : First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

enthalten in: Nature medicine | 2024

von Fizazi, K. | Azad, A. | Matsubara, N. | +18

ErratumFor: Nat Med. 2024 Jan;30(1):257-264. - PMID 38049622

5

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer : the phase 3 TALAPRO-2 trial

enthalten in: Nature medicine | 2024

von Fizazi, K. | Azad, A. | Matsubara, N. | +18

ErratumIn: Nat Med. 2024 Jan 31;:. - PMID 38297094

6

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer : the phase 3 TALAPRO-2 trial

enthalten in: Nature medicine | January 2024

von Fizazi, K. | Azad, A. | Matsubara, N. | +18

7

Publisher correction : first-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer : the phase 3 TALAPRO-2 trial

enthalten in: Nature medicine | 31 January 2024

von Fizazi, K. | Azad, A. | Matsubara, N. | +18

8

Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer : The CABASTY Phase 3 Randomized Clinical Trial

enthalten in: JAMA oncology | 2023

von Oudard, S. | Ratta, R. | Voog, E. | +24

CommentOn: JAMA Oncol. 2023 Dec 1;9(12):1638-1639. - PMID 37883113

9

Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial

enthalten in: EJHaem | 2023

von Richardson, P. | Facon, T. | Venner, C. | +18

10

Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration : Final Results from the Phase 2 TRITON2 Study

enthalten in: European urology | 2023

von Abida, W. | Campbell, D. | Patnaik, A. | +27

1
2
3
4
5
6
7
8
9
Nächster »
[9]